Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GENZYME - THE KING OF THE BIOTECHS -- Ignore unavailable to you. Want to Upgrade?

To: Racso who wrote (370)	4/30/1999 7:28:00 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 410

Rasco, these figures are less lopsided and more meaningful, thanks. With respect to cash flow/share - I was talking about cash alone (as opposed to cash flow) per share being more meaningful than book value in Genzyme's case. I have thought for some time that Amgen is way out there - its growth rate is slow, Transkaryotic looks like a real threat to their bread and butter, and nothing in the pipeline appears able to power serious growth like the other companies you mention.